Literature DB >> 19596112

Non-arteritic anterior ischaemic optic neuropathy: a review and update.

Nathan M Kerr1, Shenton S S L Chew, Helen V Danesh-Meyer.   

Abstract

Non-arteritic anterior ischaemic optic neuropathy (NAION) is the most common acute optic neuropathy in people aged 50 years and older. The condition is caused by infarction of the laminar or retrolaminar portion of the optic nerve head supplied by the short posterior ciliary arteries (SPCAs). The underlying aetiology and pathophysiology is poorly elucidated. Factors that have been implicated include nocturnal hypotension, impaired autoregulation of the microvascular supply, vasculopathic occlusion, and venous insufficiency. These factors are thought to result in axonal oedema causing a compartment syndrome in a structurally crowded optic disc leading to axonal degeneration and loss of retinal ganglion cells via apoptosis. Clinically NAION is characterised by sudden, usually painless, loss of vision in one or both eyes. Examination findings include decreased visual acuity, a visual field defect, decreased colour vision, a relative afferent pupillary defect, and optic disc swelling. Despite significant research, treatment options for NAION remain limited.

Entities:  

Mesh:

Year:  2009        PMID: 19596112     DOI: 10.1016/j.jocn.2009.04.002

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  42 in total

1.  Could Buerger's disease cause nonarteritic anterior ischemic optic neuropathy?: a rare case report.

Authors:  Anil Korkmaz; Omer Karti; Dilek Top Karti; Bora Yüksel; Mehmet Ozgur Zengin; Tuncay Kusbeci
Journal:  Neurol Sci       Date:  2018-04-05       Impact factor: 3.307

2.  Pegylated interferon alpha-associated optic neuropathy.

Authors:  Kathleen T Berg; Bruce Nelson; Andrew R Harrison; Linda K McLoon; Michael S Lee
Journal:  J Neuroophthalmol       Date:  2010-06       Impact factor: 3.042

3.  Glutathione-S-Transferase Deletions and Non-arteritic Anterior Ischemic Optic Neuropathy.

Authors:  Wencui Wan; Tao Peng; Xuemin Jin; Qiuming Li; Fengyan Zhang; Guangying Zheng; Yong Lv; Guangming Wan; Yu Zhu
Journal:  Mol Neurobiol       Date:  2015-05-20       Impact factor: 5.590

4.  Levodopa as a possible treatment of visual loss in nonarteritic anterior ischemic optic neuropathy.

Authors:  Deanna P Lyttle; Lenworth N Johnson; Edward A Margolin; Richard W Madsen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-10-20       Impact factor: 3.117

5.  An Experimental Animal Model of Photodynamic Optic Nerve Head Injury (PONHI).

Authors:  Dimosthenis Mantopoulos; Peggy Bouzika; Athanassios Tsakris; Basil S Pawlyk; Michael A Sandberg; Joan W Miller; Joseph F Rizzo Iii; Demetrios G Vavvas; Dean M Cestari
Journal:  Curr Eye Res       Date:  2016-05-09       Impact factor: 2.424

6.  Magnetic resonance imaging findings in giant cell arteritis.

Authors:  N M D'Souza; M L Morgan; S J Almarzouqi; A G Lee
Journal:  Eye (Lond)       Date:  2016-02-26       Impact factor: 3.775

7.  Ciliary neurotrophic factor (CNTF)-mediated ganglion cell survival in a rodent model of non-arteritic anterior ischaemic optic neuropathy (NAION).

Authors:  Michaela K Mathews; Yan Guo; Patricia Langenberg; Steven L Bernstein
Journal:  Br J Ophthalmol       Date:  2014-10-21       Impact factor: 4.638

Review 8.  Nonarteritic anterior ischemic optic neuropathy (NAION) and its experimental models.

Authors:  Steven L Bernstein; Mary A Johnson; Neil R Miller
Journal:  Prog Retin Eye Res       Date:  2011-03-02       Impact factor: 21.198

9.  Bilateral vision loss due to Leber's hereditary optic neuropathy after long-term alcohol, nicotine and drug abuse.

Authors:  Johanna Maass; Egbert Matthé
Journal:  Doc Ophthalmol       Date:  2018-01-25       Impact factor: 2.379

10.  Sustained neuroprotection from a single intravitreal injection of PGJ2 in a rodent model of anterior ischemic optic neuropathy.

Authors:  Valerie Touitou; Mary A Johnson; Yan Guo; Neil R Miller; Steven L Bernstein
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-11-11       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.